💊Takara Bio acquires exclusive license with new iPS cell production method
Takara Bio Co., Ltd. has concluded a license agreement for iPS cell production technology using measles virus vector, which is a vector for introduction of a novel gene possessed by Kyushu University, and has obtained exclusive license for worldwide notification. To do.
The Company co-developed iPS cell production technology development using measles virus vector with ALA Advanced Medical Science Collaborative Research Division, the University of Tokyo Medical Research Institute, the inventor of the present technology, and National Institute of Infectious Diseases Research We are conducting research.
The measles virus vector is capable of gene transfer to highly immune cells, hematopoietic stem cells and the like with high efficiency, since genes are not incorporated into the chromosome because the loaded gene is transcribed and translated only in the cytoplasm, and iPS cells can be transfected efficiently Can be manufactured.
News Release | TAKARA BIO INC. | TAKARA BIO INC.